Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.58 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.43 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16211896 | 1.00 | CNR2 (0.58) | CNR2AKT1SMPD3DYRK3PIM3 | |
| SCHEMBL16222625 | 0.82 | CNR2 (0.44) | CNR2 | |
| SCHEMBL16212291 | 0.82 | CNR2 (0.44) | CNR2 | |
| SCHEMBL16211459 | 0.82 | CNR2 (0.57) | CNR2 | |
| SCHEMBL16212085 | 0.82 | CNR2 (0.57) | CNR2 | |
| SCHEMBL20171912 | 0.75 | HTT (0.38) | CNR2 | |
| SCHEMBL16211833 | 0.74 | CNR2 (1.00) | CNR2 | |
| SCHEMBL16211882 | 0.74 | CNR2 (1.00) | CNR2 | |
| SCHEMBL20171873 | 0.73 | CNR2 (0.37) | CNR2 | |
| SCHEMBL16211771 | 0.73 | CNR2 (1.00) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991987-B1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2018-05-23 | — | — | EP | disclosed |
| US-9505762-B2 | Purine derivatives as CB2 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2991987-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20160046631-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2014177490-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046631-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | CNR1, CNR2, P2RY1 | CNR2 2/4885AKT1 1500/4885SMPD3 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.